基于二代测序技术的儿童急性淋巴细胞白血病基因突变谱及其预后意义
回顾性分析2016年11月至2019年12月福建医科大学附属协和医院141例初治儿童急性淋巴细胞白血病(ALL)患儿,采用靶向外显子二代测序(NGS)检测基因突变。83例(58.9%)检出体细胞突变,KRAS最常见(12.5%)。突变组T-ALL及融合基因阴性比例显著高于无突变组;融合基因阴性伴Ⅰ类突变者及B-ALL伴TP53突变者预计3年无事件生存(EFS)率显著降低。结论认为NGS可作为传统MICM分型的重要补充。
要点
- 141例初治儿童ALL中83例(58.9%)检出体细胞突变,KRAS最常见(12.5%),其次NOTCH1(11.9%)和NRAS(10.6%)。
- 每例T-ALL平均突变个数显著高于B-ALL(4.16±1.33 vs 2.04±0.92,P=0.004)。
- 融合基因阴性伴Ⅰ类突变者预计3年EFS率显著低于无Ⅰ类突变者(85.5% vs 100.0%,P=0.039)。
核心结论
- 体细胞突变在儿童ALL中较为常见,与临床表型及预后具有一定的相关性。
- NGS可作为传统形态学、免疫学、细胞遗传学和分子生物学(MICM)分型检查的重要补充。
研究设计与样本
- 回顾性分析2016年11月至2019年12月福建医科大学附属协和医院141例初治ALL患儿。
- 采用靶向外显子二代测序(NGS)技术行基因突变检测,分析基因突变谱及其对预后的影响。
主要发现
- 141例中83例(58.9%)检出体细胞突变,包括37个Ⅰ类及123个Ⅱ类突变位点,单核苷酸变异(SNV)为最常见突变类型。
- KRAS(20/160,12.5%)为最常见突变基因,其次为NOTCH1(11.9%)及NRAS(10.6%)。
- RAS通路(KRAS、FLT3、PTPN11)、PAX5及TP53突变仅在B-ALL患儿中检出,FBXW7、PTEN突变仅在T-ALL患儿中检出;NRAS突变主要在B-ALL中检出,NOTCH1突变主要在T-ALL中检出。
- 每例T-ALL患儿检出的平均基因突变个数显著高于B-ALL患儿(4.16±1.33 vs 2.04±0.92,P=0.004)。
- 突变组T-ALL及融合基因阴性患儿比例显著高于无突变组(P分别为0.021和<0.001);两组性别、年龄、初诊白细胞计数、微小残留病监测结果、预计3年EFS率及OS率差异均无统计学意义(P值均>0.05)。
关键数值与推荐
- 在融合基因阴性的患儿中,有Ⅰ类突变的患儿预计3年EFS率显著低于无Ⅰ类突变的患儿(85.5% vs 100.0%,P=0.039)。
- 在B-ALL患儿中,伴TP53突变的患儿预计3年EFS率显著低于不伴有TP53突变的患儿(37.5% vs 91.2%,P<0.001)。
临床怎么用
- 原文结论认为NGS可作为传统MICM分型检查的重要补充,未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study analyzed the correlation between genetic mutation and prognostic significance in childhood acute lymphoblastic leukemia (ALL) . Methods: Targeted exome by next-generation sequencing (NGS) technology was used to carry out molecular profiling of untreated 141 children with ALL in Fujian Medical University Union Hospital from November 2016 to December 2019. Correlation of genetic features and clinical features and outcomes was analyzed. Results: Among the 141 pediatric patients with ALL, 160 somatic mutations were detected in 83 patients (58.9% ) , including 37 grade Ⅰ mutations and 123 grade Ⅱ mutations. Single nucleotide variation was the most common type of mutation. KRAS was the most common mutant gene (12.5% ) , followed by NOTCH1 (11.9% ) , and NRAS (10.6% ) . RAS pathway (KRAS, FLT3, PTPN11) , PAX5 and TP53 mutations were only detected, and NRAS mutations was mainly found in B-ALL while FBXW7 and PTEN mutations were only found, and NOTCH1 mutation was mainly detected in T-ALL. The average number of mutations detected in each child with T-ALL was significantly higher than in children with B-ALL (4.16±1.33 vs 2.04±0.92, P=0.004) . The children were divided into mutation and non-mutation groups according to the presence or absence of genetic variation. There were no statistically significant differences in sex, age, newly diagnosed white blood cell count, minimal or measurable residual disease monitoring results, expected 3-year event-free survival (EFS) and overall survival (OS) between the two groups (P>0.05) . On the other hand, the proportion of T-ALL and fusion gene negative children in the mutant group was significantly higher than the non-mutation group (P=0.021 and 0.000, respectively) . Among the patients without fusion gene, the EFS of children with grade I mutation was significantly lower than children without grade I mutation (85.5% vs 100.0% , P=0.039) . Among children with B-ALL, the EFS of those with TP53 mutation was significantly lower than those without TP53 mutation (37.5% vs 91.2% , P<0.001) . Conclusion: Genetic variation is more common in childhood ALL and has a certain correlation with clinical phenotype and prognosis. Therefore, targeted exome by NGS can be used as an important supplement to the traditional morphology, immunology, cytogenetics, and molecular biology classification. 目的: 分析儿童急性淋巴细胞白血病(ALL)的基因突变谱及其预后意义。 方法: 回顾性分析2016年11月至2019年12月福建医科大学附属协和医院采用二代测序技术(NGS)行基因突变检测的141例初治ALL患儿的临床资料,分析基因突变谱及其对ALL患儿预后的影响。 结果: 141例患儿中,83例(58.9%)检出体细胞突变,包括37个Ⅰ类及123个Ⅱ类突变位点。单核苷酸变异(SNV)为最常见的突变类型。KRAS(20/160,12.5%)为最常见的突变基因,其次为NOTCH1(11.9%)及NRAS(10.6%)。RAS通路(KRAS、FLT3、PTPN11)、PAX5及TP53突变仅在B-ALL患儿中检出,而FBXW7、PTEN突变仅在T-ALL患儿中检出;NRAS突变主要在B-ALL中检出,而NOTCH1突变主要在T-ALL中检出。每例T-ALL患儿检出的平均基因突变个数显著高于B-ALL患儿(4.16±1.33对2.04±0.92,P=0.004)。按照有无遗传变异将患儿分为突变组和无突变组,两组的性别、年龄、初诊白细胞计数、微小残留病监测结果、预计3年无事件生存(EFS)率及总生存(OS)率差异均无统计学意义(P值均>0.05);但突变组T-ALL以及融合基因阴性患儿的比例显著高于无突变组(P值分别为0.021和<0.001)。进一步亚组分析,在融合基因阴性的患儿中,有Ⅰ类突变的患儿预计3年EFS率显著低于无Ⅰ类突变的患儿(85.5%对100.0%,P=0.039);在B-ALL患儿中,伴TP53突变的患儿预计3年EFS率显著低于不伴有TP53突变的患儿(37.5%对91.2%,P<0.001)。 结论: 体细胞突变在儿童ALL中较为常见,与临床表型及预后具有一定的相关性,NGS可作为传统MICM分型检查的重要补充。.
引用
- Zheng YZ, Zheng H, Chen ZS, et al. [Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35231988. doi:10.3760/cma.j.issn.0253-2727.2022.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。